Faron Pharmaceuticals Oy (LON:FARN) (NASDAQFIRSTNORTH:FARON) has said it is donating interferon beta-1a drug supplies to treat 2,000 patients taking part in a globally crucial coronavirus (COVID-19) study.
The World Health Organisation’s Solidarity trial is assessing four drug options, including the Faron candidate, known as Traumakine, in combination with the HIV drug lopinavir.
They will be compared with the current standard of care in order to assess efficacy.
Faron believes its interferon beta-1a drug may help protect against serious lung complications.
“We are very proud to support the WHO’s global effort against COVID-19 by providing a potential therapy to treat acute respiratory distress syndrome (ARDS) that significantly impacts patients with severe COVID-19,” the company’s chief executive, Dr Markku Jalkanen said in a statement.
Published at Mon, 27 Apr 2020 06:57:00 +0000-Faron Pharma donates drug for landmark World Health Organisation coronavirus trial